FDA ReviewedUpdated July 5, 2026

Tirzepatide Guide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that activates two incretin hormone pathways simultaneously. It is FDA-approved for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound, and has demonstrated superior weight loss outcomes compared to semaglutide in head-to-head trials.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesMounjaro, Zepbound
FDA StatusFDA-approved for type 2 diabetes as Mounjaro (2022); FDA-approved for chronic weight management as Zepbound (2023)[1][2]
Approval DateNovember 8, 2023[1]

How Tirzepatide Works

Tirzepatide is a "twincretin" that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation enhances insulin secretion, reduces glucagon, and may also act directly on fat tissue to improve metabolism. This dual mechanism produces greater weight loss than GLP-1-only agents like semaglutide.[3][5]

Dosing Schedule

Tirzepatide uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (max maintenance)

Side Effects

Common: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, injection site reactions, fatigue. Serious (rare): pancreatitis, gallbladder problems, hypoglycemia (especially with insulin), kidney problems, increased heart rate. Same thyroid tumor precautions as semaglutide apply.[1][3]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SURMOUNT-1 trial (N=2,539), tirzepatide at the 15mg dose achieved an average weight loss of 22.5% over 72 weeks — nearly double the results seen with semaglutide. Participants on 10mg lost an average of 21.4%, and those on 5mg lost 15.0%, all versus 2.5% placebo.[3][4]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Tirzepatide

These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.

8.6/ 10
Verified partner

Enhance MD

Best for: lab-monitored compounded GLP-1 with mandatory video visit

★★★★☆4.3

Editorial score · methodology

$49/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Enhance MD review →
8.5/ 10
Verified partner

Embody

Best for: lowest first-month entry pricing on compounded GLP-1s

★★★★☆4.3

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Embody review →
8.2/ 10
Verified partner

Telos Rx

Best for: Needle-free and microdosed compounded GLP-1 options with lab-monitored care

★★★★☆4.1

Editorial score · methodology

$49/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Telos Rx review →
8.1/ 10
Verified partner

Strut Health

Best for: oral-lozenge compounded GLP-1 access

★★★★☆4.1

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Strut Health review →
7.9/ 10
Verified partner

Live Vital

Best for: shoppers who want low-cost, physician-led compounded GLP-1 with peptide and hormone options

★★★★☆4

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Live Vital review →
7.9/ 10
Verified partner

Bodybuilding Health+

Best for: fitness-brand compounded GLP-1 with hormone and performance programs

★★★★☆4

Editorial score · methodology

$179/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Bodybuilding Health+ review →

Cost Comparison

Tirzepatide cost & pricing →How to get it →

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[6], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[7]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[8]. Prices may vary based on dose and promo availability.

ProviderStarting Price
AM Rx$39/moVisit
Aurelius Health Group$89/moVisit
boostAGErx$95/moVisit
Bliv$99/moVisit
Enhance MD$99/moVisit
Care Clinics$133/moVisit
Cora Health$135/moVisit
bmiMD$139/moVisit
Effecty$140/moVisit
Alan Meds$145/moVisit
Curex$149/moVisit
Embody$149/moVisit
Factor Health MD$149/moVisit
FeelGood$149/moVisit
10rx$149.67/moVisit
CoraDoc$165/moVisit
Alternate Health Club$169/moVisit
Bon Health$170/moVisit
AmberHealth$175/moVisit
Cielo$180/moVisit
Citizen Meds$185/moVisit
Eve$195/moVisit
Clinic Secret$196/moVisit
Elara Health and Wellness$196/moVisit
Alloy$199/moVisit
AZ Health$199/moVisit
Belle Health$199/moVisit
Care Bare Rx$199/moVisit
DoctorAdam$199/moVisit
Arc-1$199.99/moVisit
Carocare Wellness$200/moVisit
BeyondMD$209/moVisit
Bodybuilding Health+$209/moVisit
Avono Health$219/moVisit
Coivas$229/moVisit
Coby Health$239/moVisit
Blue Sky MD$240/moVisit
Bloom MD$245/moVisit
altRX$249/moVisit
Ark Health$249/moVisit
BloomWell Rx$249/moVisit
Bodi Envi$249/moVisit
Corsica Health$249/moVisit
Blue Haven RX$259/moVisit
Elevated Health$259/moVisit
AbundRX$279/moVisit
AVARA Rx$279/moVisit
Claya$279/moVisit
Amble$289/moVisit
Aspire Health$289/moVisit
Brightmeds$289/moVisit
EOS Health$289/moVisit
Ascend Vitality$299/moVisit
AskRx$299/moVisit
BetterMe Rx$299/moVisit
Concierge MD LA$299/moVisit
DrBrainRx$299/moVisit
DrMedHealth$299/moVisit
Eden$299/moVisit
Emerge Weight Loss$299/moVisit
AMP Health$309/moVisit
CoreAge Rx$349/moVisit
Dr. Arevitalize$349/moVisit
Elara MD$349/moVisit
Bioverse$399/moVisit
Breeze Meds$399/moVisit
Direct Meds$399/moVisit
Elevate Health$399/moVisit
Fella Health$399/moVisit
BioGlow Health$449/moVisit
Fierce Health$NaN/moVisit
Framework$100/moVisit
Lavender Sky Health$104/moVisit
Fitness RX$119/moVisit
Loop Health$125/moVisit
Found$129/moVisit
Fifty 410$133/moVisit
Jyra Health$133/moVisit
LumiMeds$133/moVisit
Good Girl Rx$139/moVisit
Luci$145/moVisit
Gala$149/moVisit
HeliMeds$149/moVisit
Heros Health$149/moVisit
Ivim Health$149/moVisit
Joi + Blokes$149/moVisit
Kin Meds$149/moVisit
MANÜ Telehealth$150/moVisit
Gimme Care$163/moVisit
HelloWellness$166/moVisit
Luma Meds$166/moVisit
Get Thin MD$179/moVisit
GetRelief Rx$179/moVisit
Kina$179/moVisit
Immortals$180/moVisit
Live Vital$183/moVisit
MaxLife$195/moVisit
Lumen Meds$195.82/moVisit
InstaRX$199/moVisit
Jently$199/moVisit
Livea$199/moVisit
Kongo$229/moVisit
Measured$229/moVisit
FitFlow$235/moVisit
Livv$249/moVisit
JustAnswer Weight Loss$249.97/moVisit
LevelUp Rx$249.97/moVisit
Maximus$249.99/moVisit
Ivy Rx$275/moVisit
Joey Med$275/moVisit
LifeRx.md$275/moVisit
LeanDose$279/moVisit
Liv Body$279/moVisit
HealthOn$290/moVisit
Levers Health$296/moVisit
Klinic$299/moVisit
Liberty$299/moVisit
Lyfe Rx$299/moVisit
Fitish$339/moVisit
FMmeds$NaN/moVisit
Fresh Day Meds$166/moVisit
Harper Meds$196/moVisit
Harmony Wellness Clinic$250/moVisit
Healthicare$264/moVisit
GoodRx$299/moVisit
Heally$299/moVisit
HealthSource$299/moVisit
HydraMed$319/moVisit
Freya Meds$332/moVisit
Invigor Medical$339/moVisit
Gaya Wellness$349/moVisit
Henry Meds$349/moVisit
Knownwell$349/moVisit
Helios Meds$349.97/moVisit
Independent Wellness$379/moVisit
iThriveMD$399/moVisit
LaSara Medical Group$399/moVisit
Lean Rx$399/moVisit
Levity$1299/moVisit
Form Health$1350/moVisit
Medical Health Institute$NaN/moVisit
WellMedRx$0/moVisit
Roen Rx$39/moVisit
Wisp$54/moVisit
The Virtual NP$75/moVisit
RxPepsDirect$84/moVisit
Noom Med$99/moVisit
Southern Vitality and Weight Loss$99/moVisit
Telos Rx$99/moVisit
VitaStir$99/moVisit
YourEra$99/moVisit
Primary Clinic (Direct GLP)$110/moVisit
Trimi Health$125/moVisit
TRYM Health$126/moVisit
NuuVim$133/moVisit
OurView Health$135/moVisit
Potere Health MD$135/moVisit
Teleios Health$139/moVisit
NewSelf$144/moVisit
RxPros$144.97/moVisit
MedLeanRx$149/moVisit
MyFastRx$149/moVisit
Nalena$149/moVisit
Oak$149/moVisit
Ozari Health$149/moVisit
PeterMD$149/moVisit
SnagRx$149/moVisit
Vitara RX$149/moVisit
Midi Health$150/moVisit
Mint Med$159/moVisit
Somi Health$165/moVisit
Ondra Health$166/moVisit
Pomegranate Health$166/moVisit
Shapely$166/moVisit
Try Ageless$169/moVisit
NuviaRx$170/moVisit
Zeuss$175/moVisit
Nurx$179/moVisit
YOURx Health$179/moVisit
NativeMed$183/moVisit
RxION Health$183/moVisit
NexLife$186/moVisit
Navio MD$189/moVisit
RxSaludable$189/moVisit
VitaFusions IV$189/moVisit
WePeptideRx$189/moVisit
Trava Health$198/moVisit
MediRX$199/moVisit
Nucore Health$199/moVisit
Piper$199/moVisit
Precision Telemed$199/moVisit
Rivo Health$199/moVisit
Ryze Rx$199/moVisit
Sprout Health$199/moVisit
Strut Health$199/moVisit
Tablet Health$199/moVisit
Trillium Meds$199/moVisit
Trinity Meds$199/moVisit
Velvet Rx$199/moVisit
Woodwork$199/moVisit
Zera Health$199/moVisit
Vytora Health$200/moVisit
YourHealthRx$210/moVisit
TelePeptide$214/moVisit
TRT Nation$219/moVisit
NuvaHealth$229/moVisit
Peak Wellness$229/moVisit
Tonik Wellness$229/moVisit
ZYP Medical$233/moVisit
Whoosh Wellness$235/moVisit
Mochi Health$238/moVisit
Sunlight$239/moVisit
Vaylen$239/moVisit
PepHaūs$246/moVisit
OnlyRx$249/moVisit
PauseRX$249/moVisit
PlexusDx$249/moVisit
TOM Weight Loss$249/moVisit
Transparent Meds$249/moVisit
Tyde Wellness$249/moVisit
Medsol RX$250/moVisit
NP2GO$250/moVisit
Optimized Health$250/moVisit
ReadyRx$255/moVisit
Yucca Health$258/moVisit
Mevo Health$259/moVisit
Rejuve Meds$265/moVisit
REMEVi$269/moVisit
Vital Edge$269/moVisit
WeightCare$275/moVisit
Welling Health$275/moVisit
PrescribedRX$276/moVisit
Onyx Weight Loss$280/moVisit
Somira Health$284.99/moVisit
ReflexMD$297/moVisit
RNK Health$297/moVisit
TMates$297/moVisit
TeleZen MD$298/moVisit
Mint Medical Clinic$299/moVisit
Options Medical Weight Loss$299/moVisit
OrderlyMeds$299/moVisit
PrideRx$299/moVisit
Semaglutide Online$299/moVisit
ShedRx$299/moVisit
Silhouette MD$299/moVisit
Spry$299/moVisit
Zappy Health$299/moVisit
PeptidesRx$309/moVisit
RxSpan MD$329/moVisit
VyrarX$329/moVisit
MEDVi$349/moVisit
Mixx Health & Wellness$NaN/moVisit
Nova MD$199/moVisit
Obu Health$239/moVisit
Novi$283/moVisit
MyStart Health$299/moVisit
NiceRx$299/moVisit
NuDay Rx$329/moVisit
Neo Soma Healthcare$330/moVisit
Nouri$NaN/moVisit
Remi Meds$349/moVisit
Rex MD$349/moVisit
Synergy Rx$349/moVisit
Zealthy$351/moVisit
OnlineSemaglutide.org$399/moVisit
PlushCare$399/moVisit
Prime Health$399/moVisit
Remedy Meds$399/moVisit
RestorLife Med$399/moVisit
Super Healthy Rx$399/moVisit
TeleCareSpot$399/moVisit
TeleDocs360$399/moVisit
Vyora Wellness$399/moVisit
Willow$399/moVisit
Premium Health$445/moVisit
Valhalla Vitality$449/moVisit
Royal Medical Center$450/moVisit
Shape Vantage$599/moVisit
T2D.com$999/moVisit
NowPatient$1069/moVisit

Tirzepatide Head-to-Head Comparisons

Short-form verdict pages comparing Tirzepatide to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

Tirzepatide vs Semaglutide
SURMOUNT-5 head-to-head: tirzepatide -20.2% body weight vs semaglutide -13.7% at 72 weeks. Semaglutide wins on CV outcomes (SELECT -20% MACE). Compare mechanisms and access.
Last verified 2026-05-27

See all drug-vs-drug verdicts.

Pivotal Tirzepatide Trial Walkthroughs

Endpoint-by-endpoint breakdowns of the trials that shaped the Tirzepatide label, with primary-source numbers and FAQs.

SURMOUNT-1
SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) to once-weekly tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. The 15-mg arm lost a mean 20.9% of body weight on the treatment-regimen estimand (NEJM publication) vs 3.1% with placebo; 91% achieved at least 5% loss and 57% achieved at least 20% loss. Every prespecified cardiometabolic measure — waist, systolic blood pressure, fasting insulin, triglycerides, HbA1c — improved. GI adverse events were dose-dependent and discontinuations for AEs ran 4.3-7.1% on tirzepatide vs 2.6% on placebo.
3 · N=2,539 · Last verified 2026-05-27
SURMOUNT-5
SURMOUNT-5 is the first and only randomized head-to-head trial comparing tirzepatide (Zepbound) with semaglutide (Wegovy) in adults with obesity but without type 2 diabetes. Eli Lilly randomized 751 participants 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) for 72 weeks. The least-squares mean weight loss was −20.2% with tirzepatide vs −13.7% with semaglutide (P<0.001), a 6.5-percentage-point advantage. Tirzepatide also produced a larger waist-circumference reduction (−18.4 cm vs −13.0 cm) and roughly double the proportion of participants reaching ≥25% weight loss (36.5% vs 18.6%). Gastrointestinal adverse-event profiles were broadly similar, with vomiting and GERD numerically less common on tirzepatide and injection-site reactions more common.
Phase 3b · N=751 · Last verified 2026-05-27
SURPASS-2
SURPASS-2 (Frias 2021 NEJM, PMID 34170647) is the first registrational head-to-head comparison of two incretin agonists. 1,879 adults with type 2 diabetes inadequately controlled on metformin were randomized to once-weekly subcutaneous tirzepatide 5 mg, 10 mg, 15 mg, or semaglutide 1 mg for 40 weeks. Tirzepatide produced larger reductions in HbA1c (−2.01 to −2.30 percentage points vs −1.86 with semaglutide) and in body weight (−7.6 to −11.2 kg vs −5.7 kg) across every dose, with a similar GI-event profile and low hypoglycemia in both groups. The trial supplied the regulatory case that dual GIP/GLP-1 agonism delivers more glycemic and weight effect per dose than the leading GLP-1 monotherapy at its highest then-approved T2D dose.
Phase 3 · N=1,879 · Last verified 2026-05-27
SURMOUNT-OSA
SURMOUNT-OSA is the pair of phase-3 trials that drove the December 2024 FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for the condition. Eli Lilly ran two parallel master-protocol cohorts and reported them as one paper (Malhotra 2024 NEJM, PMID 38912654): SURMOUNT-OSA-1 (n=234) randomized adults not using positive airway pressure (PAP) therapy, and SURMOUNT-OSA-2 (n=235) randomized adults already established on PAP. After 52 weeks of weekly tirzepatide at maximum tolerated dose (10 or 15 mg), the apnea-hypopnea index dropped by 25.3 events/hour in cohort 1 (placebo-subtracted −20.0) and 29.3 events/hour in cohort 2 (placebo-subtracted −23.8). Body weight fell about 18-20%, hsCRP dropped roughly 35-40%, and systolic blood pressure fell 7-9 mmHg.
Phase 3 · N=469 · Last verified 2026-05-28

Tirzepatide Patient Questions, Answered

Real patient questions about Tirzepatide pulled from named subreddits and answered with peer-reviewed trial data.

Top 10 Tirzepatide Questions from Reddit, Answered with Trial Data
10 questions · 11 PubMed citations
Last verified 2026-05-27
Top 10 Compounded vs Brand GLP-1 Questions from Reddit, Answered
10 questions · 10 PubMed citations
Last verified 2026-05-27

Ranked PubMed Studies on Tirzepatide

Curated lists of the highest-impact peer-reviewed studies on Tirzepatide and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

Top 10 PubMed Studies on Tirzepatide for Weight Loss (2026)
Ten peer-reviewed tirzepatide weight-loss studies anchored to the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, plus SURMOUNT-CN and SURMOUNT-OSA), the SYNERGY-NASH liver-fibrosis trial, the SUMMIT HFpEF trial, and the SURPASS-2 head-to-head against semaglutide. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top 10 PubMed Studies on GLP-1 Receptor Agonists for Kidney Disease (2026)
Ten peer-reviewed studies that built the kidney-outcomes case for GLP-1 receptor agonists. FLOW (2024) is the only dedicated CKD pivotal trial and drove the January 2025 FDA kidney label for Ozempic. The other nine are renal-endpoint analyses from major cardiovascular outcomes trials (LEADER, REWIND, SUSTAIN-6, AMPLITUDE-O, ELIXA, SURPASS-4), the AWARD-7 dedicated moderate-to-severe CKD trial in dulaglutide, the FLOW SGLT2 interaction analysis, and a Lancet class-level meta-analysis. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top 10 PubMed Studies on GLP-1 Agonists for MASH and MASLD (2026)
Ten peer-reviewed studies that built the GLP-1-class case in metabolic-dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease (MASLD, formerly NAFLD). Covers SYNERGY-NASH (tirzepatide phase 2), the ESSENCE phase 3 semaglutide trial, the Newsome 2020 phase 2 semaglutide NASH biopsy trial, the survodutide and retatrutide phase 2 readouts, the foundational LEAN liraglutide trial, semaglutide in MASH-related cirrhosis, the pemvidutide IMPACT phase 2b trial, the SURPASS-3 MRI liver-fat substudy of tirzepatide, and the 2025 Mantovani class-level meta-analysis. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top 10 PubMed Studies on Retatrutide (Triple Agonist GLP-1/GIP/Glucagon) 2026
Ten peer-reviewed retatrutide studies tracing Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist from molecular discovery (Coskun 2022) through phase 1b (Urva 2022), the pivotal phase 2 obesity (Jastreboff 2023) and T2D (Rosenstock 2023) trials, MASLD (Sanyal 2024), body composition (Coskun 2025), kidney parameters (Heerspink 2025), the TRANSCEND-CKD phase 3 design (Heerspink 2025), gastric emptying mechanism (Urva 2023), and patient-reported eating attitudes (Kanu 2025). Phase 3 TRIUMPH trials are still pending publication as of May 2026. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27

Related Research on Tirzepatide

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Endoscopic Sleeve Gastroplasty (ESG): The Evidence vs GLP-1s and Surgery
Endoscopic sleeve gastroplasty (ESG) is an incisionless stomach-tightening procedure that produced 13.6% weight loss in the MERIT randomized trial - on par with semaglutide, below tirzepatide and surgery. The honest evidence on efficacy, safety, cost, reversibility, and how it compares to a GLP-1.
12 min read12 citations
Gastric Balloon vs GLP-1: Which Wins on Weight Loss, Durability, and Safety?
No head-to-head trial exists, but the shape is clear: a temporary 6-month gastric balloon delivers ~7-15% weight loss that partly reverses after removal, versus a GLP-1's ongoing ~15-21% sustained while taken. The balloon also carries FDA death reports a GLP-1 does not. For most people a GLP-1 or ESG is stronger; the balloon's niche is a short-term jump-start.
10 min read7 citations
ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence
A one-time incisionless procedure or a weekly injection for life? ESG produced ~13.6-16% weight loss vs ~14.9% for semaglutide and ~20.9% for tirzepatide, but no head-to-head trial exists. Efficacy, durability, cost over time, risk, and the combination that beats either alone.
12 min read6 citations
Zepbound (Tirzepatide) and Sex Drive in Women: The Evidence
Zepbound is the largest-weight-loss GLP-1/GIP brand, so its weight-loss-mediated boost to female sexual function may be the biggest of any drug — yet no trial has ever measured female libido as an endpoint. What the evidence supports, plus PCOS and the contraception warning.
10 min read14 citations
Zepbound and Erectile Dysfunction: The Biggest Weight-Loss Lever for ED?
Zepbound (tirzepatide) produces the largest weight loss of any approved agent (SURMOUNT-1 -20.9%), so it offers the biggest weight-mediated erectile opportunity. But there is no direct ED-endpoint trial and no head-to-head vs semaglutide - plausible, not proven.
10 min read11 citations
Mounjaro and Erectile Dysfunction in Type 2 Diabetes: The Dual-Driver Case
Diabetic ED is extremely common. Mounjaro (tirzepatide) improves both glycemia and weight - the two biggest reversible drivers of ED in diabetic men. No tirzepatide trial measured erections, and established neuropathy caps recovery, but the mechanism is well-aimed.
10 min read11 citations

Frequently Asked Questions

Sources & methodology — as of July 2026
  1. 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  3. 3.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  4. 4.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  5. 5.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  6. 6.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  7. 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  8. 8.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.